NASDAQ:TBPH

Theravance Biopharma (TBPH) Stock Price, News & Analysis

$9.17
-0.05 (-0.54%)
(As of 04/24/2024 ET)
Today's Range
$9.05
$9.26
50-Day Range
$8.52
$9.92
52-Week Range
$8.21
$11.98
Volume
297,148 shs
Average Volume
405,107 shs
Market Capitalization
$445.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.50

Theravance Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
123.6% Upside
$20.50 Price Target
Short Interest
Bearish
17.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$10,922 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.84) to ($0.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.86 out of 5 stars

Medical Sector

542nd out of 907 stocks

Pharmaceutical Preparations Industry

245th out of 418 stocks

TBPH stock logo

About Theravance Biopharma Stock (NASDAQ:TBPH)

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

TBPH Stock Price History

TBPH Stock News Headlines

A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
Theravance Biopharma Inc (TBPH)
Theravance Biopharma Q4 2023 Earnings Preview
Theravance Biopharma, Inc. (TBPH)
See More Headlines
Receive TBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
4/25/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TBPH
Previous Symbol
NASDAQ:TBPHV
Fax
N/A
Employees
359
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.50
High Stock Price Target
$21.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+123.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-55,190,000.00
Pretax Margin
-85.80%

Debt

Sales & Book Value

Annual Sales
$57.42 million
Book Value
$4.28 per share

Miscellaneous

Free Float
45,209,000
Market Cap
$445.30 million
Optionable
Optionable
Beta
0.36
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

TBPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Theravance Biopharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TBPH shares.
View TBPH analyst ratings
or view top-rated stocks.

What is Theravance Biopharma's stock price target for 2024?

2 brokerages have issued 12-month price objectives for Theravance Biopharma's stock. Their TBPH share price targets range from $20.00 to $21.00. On average, they predict the company's stock price to reach $20.50 in the next twelve months. This suggests a possible upside of 123.6% from the stock's current price.
View analysts price targets for TBPH
or view top-rated stocks among Wall Street analysts.

How have TBPH shares performed in 2024?

Theravance Biopharma's stock was trading at $11.24 on January 1st, 2024. Since then, TBPH stock has decreased by 18.4% and is now trading at $9.17.
View the best growth stocks for 2024 here
.

When is Theravance Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our TBPH earnings forecast
.

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma, Inc. (NASDAQ:TBPH) issued its quarterly earnings results on Monday, February, 26th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.02. The biopharmaceutical company had revenue of $17.57 million for the quarter, compared to the consensus estimate of $17.49 million. Theravance Biopharma had a negative trailing twelve-month return on equity of 19.31% and a negative net margin of 96.12%.

What ETFs hold Theravance Biopharma's stock?
What other stocks do shareholders of Theravance Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Idera Pharmaceuticals (IDRA), Pfizer (PFE) and TG Therapeutics (TGTX).

Who are Theravance Biopharma's major shareholders?

Theravance Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.08%). Insiders that own company stock include Rhonda Farnum, Richard A Graham and Rick E Winningham.
View institutional ownership trends
.

How do I buy shares of Theravance Biopharma?

Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TBPH) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners